ArticleJournal of viral hepatitis2026
Decentralised Hepatitis C Management: A Simplified, Integrated Model of Care in a Primary Health Centre in Pakistan, August 2022-June 2023.
Article in Journal of viral hepatitis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Review
- Decentralised Hepatitis C Management: A Simplified, Integrated Model of Care in a Primary Health Centre in Pakistan, August 2022-June 2023.Journal of viral hepatitis · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Pakistan has the world's highest hepatitis C virus (HCV) prevalence, yet access to HCV care remains limited. In collaboration with the Ministry of Health Sindh, Médecins Sans Frontières implemented a simplified, decentralised model for HCV screening and treatment at a government-run primary health centre (PHC) in Baldia Town, Karachi, Pakistan. This cohort study assessed treatment uptake, effectiveness, and retention among patients screened between August 2022 and July 2023. Individuals aged ≥ 12 years were screened using capillary blood rapid diagnostic tests, with HCV viraemia confirmed via GeneXpert. Viraemic patients were treated with 12- or 24-week regimens of sofosbuvir (400 mg) and daclatasvir (60 mg), depending on the fibrosis degree. Cure was defined as a sustained virological response (viral load < 10 IU/mL) at 12 weeks post-treatment (SVR12). Among 3505 individuals screened, 613 (17.5%) tested HCV-antibody positive. Of these, 610 received confirmatory viral load testing, revealing 225 (37.9%) HCV RNA positive. A total of 161 (71.6%) initiated treatment, with a median time of 5 days (IQR 2-9) from diagnosis, while 23 (10.2%) were deemed ineligible and 41 (18.2%) lost to follow-up. Of the 118 patients assessed for SVR12, 114 (96.6%) achieved cure. Overall, 91.3% of those who started treatment completed it. These findings demonstrate the effectiveness of decentralised, primary care-based HCV management in a high-burden, resource-limited setting. The model appears feasible in terms of patient-level outcomes, though broader operational feasibility-including resources and scalability-was not formally assessed. Remaining barriers to treatment initiation and follow-up need to be addressed to advance national HCV elimination goals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.